Stock-Based Compensation (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended		0 Months Ended	3 Months Ended	0 Months Ended		3 Months Ended		9 Months Ended	3 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended		1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Jul. 15, 2014 Zalicus [Member]	Sep. 30, 2014 Zalicus [Member]	Jul. 15, 2014 Minimum [Member] Zalicus [Member]	Jul. 15, 2014 Maximum [Member] Zalicus [Member]	Sep. 30, 2014 Employees Of Acquirees [Member] Zalicus [Member]	Sep. 30, 2014 Non Employees Of Acquirees [Member] Zalicus [Member]	Sep. 30, 2014 Non Employees Of Acquirees [Member] Zalicus [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member]	Sep. 30, 2013 Employee And Directors Stock Options [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member]	Sep. 30, 2013 Employee And Directors Stock Options [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member] Zalicus [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member] Minimum [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member] Minimum [Member]	Sep. 30, 2013 Employee And Directors Stock Options [Member] Minimum [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member] Maximum [Member]	Sep. 30, 2014 Employee And Directors Stock Options [Member] Maximum [Member]	Sep. 30, 2013 Employee And Directors Stock Options [Member] Maximum [Member]	Aug. 31, 2014 2014 Plan	Sep. 30, 2014 2014 Plan	Apr. 01, 2014 2011 Plan	Mar. 31, 2014 2011 Plan
Stock-Based Compensation
Authorized number of shares																									1,504,752	740,470
Increase in number of shares available for issuance																							3,000,000
Shares available for issuance																								2,818,071
Stock-based compensation expense	$ 943	$ 35	$ 1,314	$ 93		$ 355			$ 355	$ 185	$ 283
Acquisition-date fair value of assumed Zalicus equity awards attributable to precombination services					220
Number of Options
Outstanding at the beginning of the period														458,871
Granted														1,143,076
Options assumed through Zalicus merger																134,454
Exercised														(98,405)
Cancelled														(52,098)
Outstanding at the end of the period												1,585,898		1,585,898
Vested and expected to vest at end of period												1,534,073		1,534,073
Exercisable at end of period												289,667		289,667
Weighted-Average Exercise Price
Outstanding at the beginning of the period														$ 0.96
Granted														$ 7.95
Options assumed through Zalicus merger																$ 72.02
Exercised														$ 0.91
Cancelled														$ 16.85
Outstanding at the end of the period												$ 11.50		$ 11.50
Vested and expected to vest at end of period												$ 11.65		$ 11.65
Exercisable at end of period												$ 5.97		$ 5.97
Weighted-Average Remaining Contractual Term
Outstanding at end of period														9 years 1 month 6 days
Vested and expected to vest at end of period														9 years
Exercisable at end of period														7 years 6 months
Aggregate Instrinsic Value
Outstanding at end of period												7,810		7,810
Vested and expected to vest at end of period												7,556		7,556
Exercisable at end of period												1,440		1,440
Weighted average fair value
Weighted average grant-date fair value of options granted during the period														$ 6.01
Unrecognized stock-based compensation expense
Unrecognized stock-based compensation expense												$ 4,992		$ 4,992
Unrecognized stock-based compensation expense, Recognition period														3 years 5 months 23 days
Weighted-average assumptions
Risk-free interest rate					1.91%								1.81%				1.95%	1.91%	1.09%	2.01%	2.09%	1.81%
Expected volatility					66.02%								66.99%		66.99%		65.84%	64.07%		65.94%	66.07%
Expected term							1 month 6 days	6 years				6 years	6 years	6 years	6 years
Expected dividend yield												0.00%	0.00%	0.00%	0.00%